Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.
How to buy shares in Adagene
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ADAG – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Adagene stock price (NASDAQ: ADAG)
Use our graph to track the performance of ADAG stocks over time.Adagene shares at a glance
Latest market close | $1.99 |
---|---|
52-week range | $1.60 - $20.98 |
50-day moving average | $2.86 |
200-day moving average | $7.06 |
Wall St. target price | $24.69 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.83 |
Buy Adagene shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Adagene stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adagene price performance over time
Historical closes compared with the close of $1.99 from 2022-07-01
1 week (2022-06-24) | -0.50% |
---|---|
1 month (2022-06-02) | -30.42% |
3 months (2022-04-01) | -45.48% |
6 months (2021-12-31) | -75.33% |
1 year (2021-07-02) | -85.45% |
---|---|
2 years (2020-06-28) | N/A |
3 years (2019-06-28) | N/A |
5 years (2017-06-28) | N/A |
Adagene financials
Revenue TTM | $10.2 million |
---|---|
Gross profit TTM | $10.2 million |
Return on assets TTM | -33.04% |
Return on equity TTM | -66.04% |
Profit margin | 0% |
Book value | $3.59 |
Market capitalisation | $87.2 million |
TTM: trailing 12 months
Adagene share dividends
We're not expecting Adagene to pay a dividend over the next 12 months.
You may also wish to consider:
- Novo Nordisk A/S (NVO.US) (1.41% forward annual dividend yield)
Adagene overview
Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. .
Adagene in the news
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
Frequently asked questions
What percentage of Adagene is owned by insiders or institutions?Currently 10.608% of Adagene shares are held by insiders and 19.43% by institutions. How many people work for Adagene?
Latest data suggests 259 work at Adagene. When does the fiscal year end for Adagene?
Adagene's fiscal year ends in December. Where is Adagene based?
Adagene's address is: Building C14, Suzhou, China, 215123 What is Adagene's ISIN number?
Adagene's international securities identification number is: US0053291078
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert